Fresenius SE & Co KGaA (FRE.DE) Akcie Kurz
Fresenius SE & Co KGaA Kurz
Tržby rostly o 4,0 % ročně za posledních 19 let na 22,87 Mld. EUR. Zisk na akcii rostl o 6,2 % ročně za posledních 19 let. čistá marže společnosti Fresenius SE & Co KGaA je nyní 5,5 %, převážně stabilní z 4,9 % před několika lety. Fresenius SE & Co KGaA aktuálně nabízí dividendový výnos kolem 2,16 %. Výplatní poměr je kolem 45 % zisku. Dividenda rostla o 10,0 % ročně za posledních 19 let. Medián cílové ceny analytiků je 57,12 EUR, tedy nad aktuální cenu o 23,3 %. Z 23 analytiků jich 21 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Fresenius SE & Co KGaA
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Fresenius SE & Co KGaA a analýza akcií
Nejčastější otázky týkající se akcie Fresenius SE & Co KGaA
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Analytici aktuálně stanovují průměrnou cílovou cenu 56,38 EUR pro akcii Fresenius SE & Co KGaA (medián: 57,12 EUR), tedy +18,0 % vůči poslední ceně. Konsensus vychází z 23 hodnocení analytiků.
23 analytiků aktuálně hodnotí akcii Fresenius SE & Co KGaA: 21 doporučuje koupit, 2 držet a 0 prodat. Pro rok 2026 analytici očekávají u Fresenius SE & Co KGaA tržby 23,71 Mld. EUR a zisk na akcii 3,63 EUR.
Akcie Fresenius SE & Co KGaA (FRE.DE) je kótována na 10 burzách, mimo jiné: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
Tržby očekávané za Fresenius SE & Co KGaA činí 23,71 Mld. EUR. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Fresenius SE & Co KGaA činí 2,05 Mld. EUR. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Fresenius SE & Co KGaA je aktuálně 12,76. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Fresenius SE & Co KGaA.
Poměr ceny k tržbám (P/S) Fresenius SE & Co KGaA je aktuálně 1,10. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Fresenius SE & Co KGaA.
Score kvality pro Fresenius SE & Co KGaA je 2/10.
ISIN Fresenius SE & Co KGaA je DE0005785604. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Fresenius SE & Co KGaA je 578560. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Fresenius SE & Co KGaA je FRE.DE. Symbol tickeru se používá k obchodování akcií Fresenius SE & Co KGaA na burze.
Fresenius SE & Co KGaA akcie
Fresenius SE & Co KGaA Peer Group
Fresenius SE & Co KGaA Ticker
Fresenius SE & Co KGaA FIGI
Všechny fundamentální údaje o Fresenius SE & Co KGaA v podrobné analýze
Naše analýzy akcií společnosti Fresenius SE & Co KGaA zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Fresenius SE & Co KGaA. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: